NO20052177L - Anvendelse av galantamin og dets derivater for fremstilling av legemidler - Google Patents
Anvendelse av galantamin og dets derivater for fremstilling av legemidlerInfo
- Publication number
- NO20052177L NO20052177L NO20052177A NO20052177A NO20052177L NO 20052177 L NO20052177 L NO 20052177L NO 20052177 A NO20052177 A NO 20052177A NO 20052177 A NO20052177 A NO 20052177A NO 20052177 L NO20052177 L NO 20052177L
- Authority
- NO
- Norway
- Prior art keywords
- galantamine
- manufacture
- derivatives
- drugs
- post
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT15382003 | 2003-09-29 | ||
PCT/AT2004/000251 WO2005030332A2 (de) | 2003-09-29 | 2004-07-12 | Verwendung von galanthamin und seinen derivaten zum herstellen von arzneimitteln |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052177D0 NO20052177D0 (no) | 2005-05-03 |
NO20052177L true NO20052177L (no) | 2005-06-24 |
Family
ID=34382391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052177A NO20052177L (no) | 2003-09-29 | 2005-05-03 | Anvendelse av galantamin og dets derivater for fremstilling av legemidler |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060111341A1 (zh) |
EP (1) | EP1667769A2 (zh) |
CN (1) | CN1859949A (zh) |
CA (1) | CA2506282A1 (zh) |
MX (1) | MXPA05005570A (zh) |
NO (1) | NO20052177L (zh) |
WO (1) | WO2005030332A2 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
WO2008022365A2 (de) * | 2006-08-24 | 2008-02-28 | Sanochemia Ltd. | Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
CN104860955B (zh) * | 2015-04-22 | 2017-07-14 | 华东理工大学 | 加兰他敏类似物及其用途 |
US10414778B2 (en) * | 2016-04-29 | 2019-09-17 | New Mexico Tech University Research Park Corporation | Methods for treatment of resistant cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
US6407229B1 (en) * | 1994-10-21 | 2002-06-18 | Sanochemia Pharmazeutika Ag | Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine |
ES2106700T3 (es) * | 1994-10-21 | 2000-05-16 | Sanochemia Pharmazeutika Ag | Procedimiento para la preparacion de derivados de la 4a,5,9,10,11,12-hexahidro-6h-benzofuro(3a,3,2-ef)(2)benzacepinas. |
GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
CA2352564C (en) * | 1998-11-27 | 2009-05-19 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of effectors of the central cholinergic nervous system |
-
2004
- 2004-07-12 WO PCT/AT2004/000251 patent/WO2005030332A2/de not_active Application Discontinuation
- 2004-07-12 MX MXPA05005570A patent/MXPA05005570A/es not_active Application Discontinuation
- 2004-07-12 US US10/537,568 patent/US20060111341A1/en not_active Abandoned
- 2004-07-12 CA CA002506282A patent/CA2506282A1/en not_active Abandoned
- 2004-07-12 EP EP04737381A patent/EP1667769A2/de not_active Withdrawn
- 2004-09-09 CN CNA2004800283471A patent/CN1859949A/zh active Pending
-
2005
- 2005-05-03 NO NO20052177A patent/NO20052177L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2506282A1 (en) | 2005-04-07 |
WO2005030332A3 (de) | 2005-06-02 |
EP1667769A2 (de) | 2006-06-14 |
WO2005030332A2 (de) | 2005-04-07 |
NO20052177D0 (no) | 2005-05-03 |
US20060111341A1 (en) | 2006-05-25 |
CN1859949A (zh) | 2006-11-08 |
MXPA05005570A (es) | 2005-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03010134A (es) | Derivados de ciclohexan-1-4-diamina sustituidos. | |
MXPA03012013A (es) | Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor. | |
TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
MY137039A (en) | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | |
MX2007004781A (es) | Derivados de 3-arilamino piridina. | |
TW200640913A (en) | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | |
WO2005105753A3 (en) | Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom | |
NO20062599L (no) | Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav | |
PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
MXPA05004621A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes. | |
WO2002010152A3 (de) | Neue indolderivate und deren verwendung als arzneimittel | |
NO20052177L (no) | Anvendelse av galantamin og dets derivater for fremstilling av legemidler | |
ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
DE50310080D1 (de) | 3-SUBSTITUIERTE 3,4-DIHYDRO-THIENOi2,3-D PYRIMIDIN-4-ONE-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG | |
DE59904180D1 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
MY136938A (en) | New process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
MY139159A (en) | Method for synthesis of perindopril and its pharmaceutically acceptable salts | |
WO2003089449A3 (fr) | Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective | |
AU2003246694A1 (en) | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | |
AU2003201163A1 (en) | Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol | |
MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
WO2004022542A3 (de) | Substituierte 1,2,3,4-tetrahydrochinolinderivate | |
MY135359A (en) | New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof | |
MY136288A (en) | New process for the synthesis of perindopril and its pharmaceutically acceptable salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |